Given the on-target pharmacological effects of the PERK inhibitor GSK2606414 on MM cells, the development of even more potent PERK inhibitors may offer a therapeutic advantage (likely in combination with proteasome inhibitors) that would affect MM pathogenesis and treatment. This evidence concerns the gene EIF2AK3 and Miyoshi myopathy.